(400c) Considerations in Developing a Control Strategy for Continuous Direct Compression | AIChE

(400c) Considerations in Developing a Control Strategy for Continuous Direct Compression


Vanarase, A. - Presenter, Bristol-Myers Squibb
Kientzler, D., Bristol-Myers Squibb Company
Macias, K., Bristol-Myers Squibb
Stevens, T., Bristol-Myers Squibb Company
Abebe, A., Bristol-Myers Squibb
Holman, J., GEA
In this work a continuous direct compression (CDC) process was investigated for a low dose drug product for an API with cohesive material properties. The CDC process was developed on the GEA CDC-50 system. A risk based approach was followed during the entire process development of CDC. The process parameters for feeding and blending were selected such that the feeding variability is sufficiently filtered by the available residence time distribution (RTD) of the blending system. The holistic control strategy for CDC involved specifications for input materials, in-process controls for various drug product attributes including blend concentration, tablet weight and hardness, and a product release strategy. The blend concentration was monitored using an in-line NIR method and a RTD model of the CDC line as two redundant methods. In the event when the blend concentration falls outside the given specification limits, non-conforming tablets were diverted. For using the RTD model as a process monitoring method, sensitivity of RTD model to material variability and method of feed rate measurement were identified as the main risks. In this presentation, the development studies conducted to address these risks will be discussed. In addition the pros and cons of using each process monitoring method as well as considerations in designing a diversion system will be discussed.